Business Wire

Chugai's Bispecific Antibody "ERY974" Results of Preclinical Study Published in Science Translational Medicine

Jaa

Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that the preclinical study findings on its original bispecific antibody ERY974, a molecule that binds Glypican-3 and CD3 simultaneously, and that is currently under development as a Phase I clinical study for solid tumors, were published in the online edition of Science Translational Medicine on October 4, 2017 (local time) (http://stm.sciencemag.org/content/9/410/eaal4291).
Science Translational Medicine is a member of the Science Magazine family of journals and is an essential platform for peer-reviewed, multidisciplinary research driving the latest medical advances.

“ERY974 is a bispecific antibody created under the joint research between Chugai and Chugai Pharmabody Research with the application of Chugai’s proprietary innovative antibody engineering technologies. We are extremely pleased that our research findings on ERY974 have been published in Science Translational Medicine,” said Dr. Hisafumi Okabe, Senior Vice President responsible for Research and Translational Clinical Research. “It is said that cancer immunotherapy has made a paradigm shift in cancer treatment and that the role of the immune system in cancer treatment is likely to continue to grow in the future. As a cancer immunotherapy, we have high hopes that ERY974 will demonstrate anti-tumor effects in future clinical studies and become a drug that can contribute to the treatment of patients.”

Glypican-3 (GPC3) is a membrane protein that is expressed with high frequency on the cellular membranes of various tumor cells including hepatocellular carcinoma, lung cancer, and gastric cancer. GPC3 is reported to be expressed in various tissues in the fetal stage and play an important role*, but is rarely expressed in normal adult tissues*. As GPC3 expression is observed through the malignant transformation of cells, GPC3 is thought to be a protein specific to cancer (tumor-associated antigen)*.

ERY974 is a bispecific antibody that binds to both GPC3 on the cancer cell membrane and to CD3, a membrane protein expressed on T cells, a type of lymphocyte. ERY974 is a T cell Redirecting AntiBody (TRAB) created with Chugai’s proprietary antibody engineering technology, and while simultaneously binding to GPC3 and CD3 and directing T cells to cancer cells, it also activates T cells, specifically attacking and killing neighboring cancer cells. Based on this mechanism whereby it activates T cells and attacks cancer cells, TRAB is classified as a type of cancer immunotherapy.

The following points were shown in this research:

  • According to the immunohistochemistry, GPC3 is expressed in various cancers (a hepatocellular carcinoma, a squamous lung cancer, a small cell lung cancer, an esophageal cancer, a gastric cancer and a head and neck cancer), and as previously reported *, it is rarely expressed in normal tissues (30 different tissues) (in vitro)
  • GPC3-dependent T cell activation and killing of cancer cells by ERY974 was observed in vitro
  • In three different experimental tumor models using mouse, ERY974 demonstrated anti-tumor effects
  • Anti-tumor effects were observed even in cancers where other cancer immunotherapies are ineffective (Mouse)
  • Tolerability of ERY974 was observed in toxicity testing in animal

Based on the results of this preclinical study, Chugai began phase I clinical trial of ERY974 in patients with GPC3 positive solid tumors in the United States in August 2016 (NCT02748837).

As a leading company in the field of antibody therapeutics, Chugai will continue to contribute to global healthcare and the health of all people through the creation of innovative treatments using its proprietary antibody technologies.

* D. Baumhoer, L, Tornillo, S. Stadlmann, M. Roncalli, E. K. Diamantis, L. M. Terracciano, Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol. 129, 899-906 (2008).

About Chugai

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2016 of Chugai totalled 491.8 billion yen and the operating income was 80.6 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.

Contact information

For Media
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
Koki Harada
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For US media
Chugai Pharma USA Inc.
Casey Astringer
Tel: +1-908-516-1350
E-mail: pr@chugai-pharm.com
***
For European media
Chugai Pharma France SAS
Nathalie Leroy
Tel: +33-1-56-37-05-21
E-mail: pr@chugai.eu
***
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou
Tel: +886-2-2715-2000
E-mail: pr@chugai.com.tw
***
For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Rimini Street Expands Investment and Operations in Europe19.10.2017 01:00Tiedote

Rimini Street, Inc., (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the appointment of industry leader Marc Chesover as general manager of Europe, the Middle East and Africa (EMEA). The Company also announced the launch of its French subsidiary, hiring of new staff and opening of its new office in Paris, France. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006654/en/ Rimini Street Expands Investment and Operations in Europe (Photo: Business Wire) Enterprise Software Veteran Leads EMEA Operations Rimini Street’s new general manager, Marc Chesover, will lead the Company’s sales and service delivery operations across EMEA, and the next p

Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy19.10.2017 00:43Tiedote

Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006639/en/ CAR T therapy is a breakthrough in hematologic cancer treatment in which

IFF Launches Re-Imagine…™ Programs to Tap Unmet Consumer Opportunities, Speed Innovation18.10.2017 23:15Tiedote

Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, launched their Re-Imagine programs to accelerate innovation and increase agility to capture unmet opportunities in the changing food and beverage market. Based on a combination of future trends analysis, consumer insights, and a modernized cross-category development process, the programs guide the Company’s research and development efforts to ensure an innovation pipeline that addresses evolving consumer needs and desires. “The Re-Imagine programs area tangible expression of our commitment to advance taste for our customers – and consumers,” said IFF Chairman and CEO Andreas Fibig. “It is another way in which we show how we are dedicated to being our customers’ partner of choice as we progress on our business strategy, imbu

Sparkol Launches VideoScribe 318.10.2017 16:24Tiedote

Introducing VideoScribe Version 3 by Sparkol. Already used by over two million people across the world to create engaging explainer videos, Version 3 of the highly intuitive software comes packed full of new features, including: An improved user experience and slick UI - animate easier than ever before Enhanced search - find exactly the image you need in record time Intelligent image recommendations - focus your creativity on your video instead Smoother performance - maximum productivity when using the software VideoScribe customers include the world’s largest brands (HP, BBC, Sky and the University of British Columbia), businesses across every sector, leading education providers, award-winning teachers, charities, campaigners, and coun

Piraeus Bank: Agreement for the Sale of Serbian Operations18.10.2017 16:06Tiedote

Piraeus Bank announces that it has entered into an agreement to sell its Serbian banking and leasing operations to Direktna Banka A.D., a local Serbian banking group that has been strongly growing its presence in the market, for a total cash consideration between €58mn up to €61mn, depending on the financial performance of the divested assets until completion of the transaction, through a combination of direct sale price and simultaneous reduction of capital in Piraeus Bank Beograd AD. The transaction is conditional upon the usual corporate and regulatory approvals, including those of the National Bank of Serbia and the Hellenic Financial Stability Fund. The transaction represents another step towards the implementation of Piraeus Bank’s Restructuring Plan commitments, as those were agreed with the Directorate General of Competition of the European Commission. The transactio

Introducing InVision Studio, The World’s Most Powerful Screen Design Tool18.10.2017 16:01Tiedote

InVision, the product design platform powering the world’s best digital experiences, today introduced Studio, a powerful new tool that will change the way screen design is done. InVision Studio was created by working closely with the world’s best design teams and finding inspiration in how they create beloved digital products. The launch of Studio comes at a time when modern organizations are shaping and redefining entire markets through their focus on digital customer experience. InVision already powers the product design process of more than 3 million people at tens of thousands of companies, including eighty percent of the Fortune 100 and brands like Airbnb, Uber, HBO, Amazon, IBM, Nike, and Slack. This new product reflects a major evolution of the digital product design workflow. With Studio, InVision has developed an end-to-end platform for designing digit

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme